Rheumatology Department, Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia.
Laboratory of Research in Immunology, Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital of Tunis, Tunis El Manar University, Tunis, Tunisia.
Drug Metab Pers Ther. 2023 Mar 16;38(2):155-162. doi: 10.1515/dmpt-2022-0176. eCollection 2023 Jun 1.
Single nucleotid polymorphisms (SNPs) of Fc-gamma receptors (FcgRs), by inducing a variation of their affinity to the Fc-region of immunoglobulins, might influence the efficacy of Fc-containing biologics prescribed in rheumatoid arthritis (RA). Our aim was to investigate associations of , and SNPs with TNF-inhibitors (TNFi)' response in Tunisian RA patients.
A cross-sectional, observational and analytic multicentric cohort study was conducted in a group of 47 Tunisian RA patients treated with (etanercept [ETA], adalimumab [ADL] and infliximab [IFX]). Treatment outcome was evaluated after 6 months. , and SNPs were genotyped.
The analytic study including all types of TNFi showed that low-affinity receptor was associated with a greater decrease of DAS28, while high-affinity receptor was associated with a lower decrease of DAS28 in ADL group. Furthermore, both of high affinity receptors and were more prevalent in non-responders to ADL, according to EULAR criteria.
Identifying reliable biomarkers of response to biologics in RA is necessary to improve responsiveness, preserve joints' functions and structure, and reduce treatment's cost. Our study showed that FCGR3A and FCGR3B polymorphisms might have an impact on TNFis' response in RA Tunisian patients since bad response was more frequent in homozygous carriers of high affinity alleles FCGR3A-V and FCGR3B-NA1.
Fc 受体（FcgR）的单核苷酸多态性（SNPs）通过诱导其与免疫球蛋白 Fc 区亲和力的变化，可能影响类风湿关节炎（RA）中规定的含 Fc 的生物制剂的疗效。我们的目的是研究 Fcγ 受体 3A（FCGR3A）和 Fcγ 受体 3B（FCGR3B）中的 、 和 SNPs 与 TNF 抑制剂（TNFi）在突尼斯 RA 患者中的反应之间的关联。
这是一项在一组接受（依那西普[ETA]、阿达木单抗[ADL]和英夫利昔单抗[IFX]）治疗的 47 例突尼斯 RA 患者中进行的横断面、观察性和分析性多中心队列研究。在 6 个月后评估治疗效果。对 、 和 SNPs 进行基因分型。
在包括所有类型 TNFi 的分析研究中，低亲和力受体与 DAS28 的更大下降相关，而高亲和力受体与 ADL 组 DAS28 的下降更低相关。此外，根据 EULAR 标准，ADL 无应答者中高亲和力受体 和 更为常见。
确定 RA 对生物制剂反应的可靠生物标志物对于提高反应性、保持关节功能和结构以及降低治疗成本是必要的。我们的研究表明，FCGR3A 和 FCGR3B 多态性可能对 RA 突尼斯患者的 TNFis 反应产生影响，因为高亲和力等位基因 FCGR3A-V 和 FCGR3B-NA1 的纯合载体更频繁地出现不良反应。
